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ABSTRACT
Background: Many meningiomas are identified by imaging and followed, with an 
assumption that they are WHO Grade I tumors. The purpose of our investigation is to 
find clinical or imaging predictors of WHO Grade II/III tumors to distinguish them 
from Grade I meningiomas.
Methods: Patients with a pathologic diagnosis of meningioma from 2002–2009 
were included if they had pre-operative MRI studies and pathology for review. 
A Neuro-Pathologist reviewed and classified all tumors by WHO 2007. All Brain MRI 
imaging was reviewed by a Neuro-radiologist. Pathology and Radiology reviews were 
blinded from each other and clinical course. Recursive partitioning was used to create 
predictive models for identifying meningioma grades.
Results: Factors significantly correlating with a diagnosis of WHO Grade II-III 
tumors in univariate analysis: prior CVA (p = 0.005), CABG (p = 0.010), paresis 
(p = 0.008), vascularity index = 4/4: (p = 0.009), convexity vs other (p = 0.014), 
metabolic syndrome (p = 0.025), non-skull base (p = 0.041) and non-postmenopausal 
female (p = 0.045). Recursive partitioning analysis identified four categories: 1. prior 
CVA, 2. vascular index (vi) = 4 (no CVA), 3. premenopausal or male, vi < 4, no CVA. 
4. Postmenopausal, vi < 4, no CVA with corresponding rates of 73, 54, 35 and 10% 
of being Grade II-III meningiomas.
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Conclusions: Meningioma patients with prior CVA and those grade 4/4 
vascularity are the most likely to have WHO Grade II-III tumors while post-
menopausal women without these features are the most likely to have Grade I 
meningiomas. Further study of the associations of clinical and imaging factors with 
grade and clinical behavior are needed to better predict behavior of these tumors 
without biopsy.
INTRODUCTION
Meningiomas are the most common non-glial brain 
tumors, representing 15–25% of all primary brain tumors 
[1]. Historically, 90–95% of meningiomas were classified 
as benign lesions, while the other 5–10% of tumors were 
classified as the more aggressive sub-types, atypical 
(Grade II) and anaplastic (Grade III) [2]. The WHO 
first classified meningioma in 1993. Using that criteria, 
even completed resected benign lesions had relatively 
high recurrence rates, approaching 20% at ten years [3]. 
Pathologists have subsequently tried to re-classify lesions 
in order to better predict biologic behavior. In 2000, the 
WHO grading system was updated using more objective 
criteria and was determined to be more reproducible [4]. 
Grade II and III lesions were determined by number of 
mitosis per ten high-powered fields (≥4), high-risk sub-
type (clear cell, choroid, papillary, and rhabdoid), and 
high-risk histologic features (three of the following 
five: small cell change, increased cellularity, prominent 
nucleoli, sheet-like growth or necrosis). In 2007, the 
WHO grading schema was modified with the major 
difference being that brain invasion could be used to 
classify otherwise grade I meningiomas as grade II. 
[5] One recent study evaluated all three pathologic 
classification systems in 196 specimens and demonstrated 
that the percentage of Grade II/III tumors increased with 
each consecutive pathologic staging system from 19.9% 
to 26.5% and to 31.1% respectively [6].
Many meningiomas are located at the skull base or 
other high-risk areas that do not facilitate easy surgical access 
for resection or even biopsy. Many other meningiomas occur 
in patients who are poor medical risk for resection or biopsy. 
Since many such meningioma are observed or irradiated 
without tissue diagnosis, we feel that a non-invasive 
approach to predict meningioma grade would be a highly 
beneficial management guide for these patients. The purpose 
of our study is to investigate whether MRI parameters, 
patient factors, co-morbidities, and/or medications could 
be used to predict lesion aggressiveness. All lesions were 
reviewed by a Neuroradiologist and a Neuropathologist in a 
blinded fashion from each other and from clinical outcomes. 
Lesions presenting prior to 2007 were re-classified according 
to the WHO 2007 grading schema.
MATERIALS AND METHODS
After obtaining IRB approval (IRB#32319EP), we 
identified meningioma patients through our tumor registry 
and by specimen records in the Pathology Department at 
Penn State Hershey Medical Center from 2002–2009. We 
originally identified 100 cases, but only 85 patients had 
pathologic specimens and MRI imaging available for review. 
A board-certified Neuropathologist and a Pathology resident 
(CS, DT) reviewed all pathology specimens using WHO 
2007 criteria completely without knowledge of clinical 
outcome or radiological imaging characteristics. Specimens 
were classified by grade, sub-type, brain invasion, bone 
invasion, cellularity, nuclear/cytoplasmic ratio, prominent 
nucleoli, sheet-like growth pattern, and foci of necrosis.
We reviewed medical charts to record patient 
factors including medications, symptoms co-morbidities 
race, age, body mass index, pregnancy, smoking/
alcohol history, and sex into a de-identified database. 
Symptoms analyzed included seizures, memory loss, 
visual loss/disturbance, headaches, nausea, vomiting, 
cranial neuropathy, hearing loss, ataxia, and paresthesias. 
Medical conditions analyzed included past therapeutic 
radiation exposure (external beam/srs to tumor or 
delivery to areas outside the CNS), osteoporosis, 
diabetes, hypertension, past myocardial infarction, 
cardiac arrhythmia, renal failure, thromboembolic 
disease, CVA, and Charlson co-morbidity index [7]. 
No patients in our series had a history of NF-1 or 
NF-2. Medications analyzed included aspirin, statins, 
NSAIDS, and hormonal therapy (estrogen replacement). 
No patients were noted to be taking 5-alpha reductase 
inhibitors, tamoxifen or oral contraceptive pills at the 
time of diagnosis.
85 of the 92 patients with available pathology had 
MRI Scans available for re-evaluation. MRI scans were 
analyzed for location, brain invasion, bone invasion, 
brain herniation, edema, hyperostosis, necrosis, vessel 
invasion, hemorrhage, calcification, cystic change, 
vascularity index, tumor volume, brain herniation/midline 
shift, and number of tumors. The vascularity index used a 
four-point grading system that was devised by the Neuro-
Radiologists at Penn State Hershey Medical Center as 
noted by: Vascularity 1- Baseline vascularity, defined by 
markedly low signal compared to the dural venous sinuses, 
typically the superior sagittal sinus; Vascularity 2 – Mild 
enhancement, but low signal compared to the superior 
sagittal sinus; Vascularity 3 – moderate enhancement with 
signal equal to the superior sagittal sinus and pituitary 
gland; and Vascularity 4 – Avidly enhancing tumor with 
high signal compared to the superior sagittal sinus. The 
four different grades for the vascular index can be seen 
in Figure 1.
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Radiologic brain invasion was noted by the loss of 
gray matter morphology and distortion as well as the loss 
of fat plane (arrows) between tumor and normal brain as 
noted in Figure 2.
Apparent diffusion coefficient was available in 44 of 
the 85 patients and classified as increased, decreased, 
mixed or same cellularity as normal brain.
Univariate analysis was performed of all patient 
characteristics, medications, symptoms, co-morbidities, 
and radiologic parameters to assess their association 
with grade I or grade II-III tumors. All factors in the 
univariate analysis with a p-value < 0.05 were analyzed 
by recursive partitioning analysis. Clusters of different 
genetic mutations have been identified among different 
locations and grades of meningiomas [8–10]. Because of 
this heterogeneity in meningiomas we felt that recursive 
partitioning analysis would be the best way to discern 
possible clusters of clinical and imaging characteristics to 
identify WHO Grade II-III meningiomas.
RESULTS
Pathology review
We identified 85 patients with both pathology and 
imaging available for review for this study. 54 (64%) were 
classified as WHO grade I while 31 (36%) were WHO 
Grade II-III; specifically with 29(34%) WHO-II and 
2 (2%) WHO-III.
The four most common histological types were 
transitional (25%), meningothelial, (23%), atypical (22%), 
and fibrous (4%). Brain invasion was seen in 6%, and 
bone invasion in 6%, Increased cellularity was identified 
Figure 1 a-d: Tumor vascularity as noted by the degree of tumor enhancement. A = Vascularity 1- Baseline vascularity; 
defined by markedly low signal (white arrow) compared to the dural venous sinuses (black arrow), typically the superior sagittal sinus, 
B = Vascularity 2 – Mild enhancement, but low signal compared to the superior sagittal sinus, C = Vascularity 3 – moderate enhancement 
with signal equal to the superior sagittal sinus and pituitary gland, D = Vascularity 4 – Avidly enhancing tumor with high signal compared 
to the superior sagittal sinus.
a
c d
b
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in 17%, high N/C ratio in 10%, prominent nucleoli in 
27%, foci of necrosis in 28%, and uninterrupted pattern of 
sheet-like growth in 21% of specimens.
Clinical characteristics
Most patients were female (68%) and white (81%). 
The median presenting age was 59.16 (range 2–86). The 
median BMI was 31.37 (obesity is BMI ≥30), with a range 
of 16.4–49. Only 3% of the patients were asymptomatic, 
and the most common presenting complaint was 
headaches that were reported in 35% of patients. Visual 
disturbances were reported in 25%, seizures in 23%, 
imbalance in 18%, memory loss in 17%, paresthesias in 
16%, and cranial neuropathies in 15%. Prior radiation 
treatment to or near the head was reported in 5%. The 
most common co-morbidity was hypertension, seen in 
56% of patients.
Imaging review
Radiological/imaging review demonstrated that the 
most common location was the cerebral convexity, seen 
in 45% of patients. Other locations were: parasellar (6%), 
falx (6%), sphenoid ridge (3%), petroclinoid (3%), orbital/
peri-orbital (2%), tentorial (2%), cerebellar pontine angle 
(2%), and other (16%). Median tumor volume was 10.13cc 
(median 5.48–12.56cc). Brain herniation/midline shift was 
seen in 45%. Vascularity of the tumors was graded with 
a vascularity index of 1, 2, 3, or 4 in 17%, 4%, 58% and 
21% of the patients respectively.
We identified radiological brain invasion in 32%. 
60% of tumors were associated with brain edema. Imaging 
evidence of necrosis was seen in 22%, blood vessel 
invasion in 10%, hyperostosis in 33%, bone invasion in 
14%, hemorrhage in 4%, calcification in 24%, and cystic 
changes in 6%.
Univariate analysis
Table 1 shows the clinical and imaging factors 
identified as significantly associated with Grade II/III by 
univariate analysis (p < 0.05) were: prior CVA73% WHO 
Grade II-III (8/11) vs 26% (18/68) without (p = 0.005), 
prior CABG surgery 100% WHO Grade II-III vs 29% 
without (p = 0.010), paresis 57% WHO II-III vs 23% 
without (p = 0.008), vascularity index = 4: 65% WHO 
Grade II-III vs 28% with vascularity index = 1–3 
(p = 0.009), site: convexity 49% WHO Grade II-III vs 
23% other (p = 0.014) , metabolic syndrome 0/8 WHO 
Grade II-III vs 40% without (p = 0.025), site: skull base 
13% WHO Grade II-III vs 42% other (p = 0.041) and 
postmenopausal female 23% yes vs 47% no (p = 0.045).
Borderline significance was seen for: multiple 
meningiomas (p = 0.060, 63% vs 32%), obesity with 
BMI >30 (p = 0.061, 22% vs 44%), and imaging 
defined brain invasion (p = 0.063, 50% vs 28%). 
Variables correlating with WHO Grade II-III at a level 
Figure 2: Brain invasion as noted by loss of fat plane (arrows) between tumor and normal brain. 
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of 0.1 < p < 0.2 were: vessel invasion, coronary artery 
disease, NSAIDS, current oral contraceptive (OCP) 
use, hypertension, Vol > 17cc, and Pre-Menopausal 
Female. Variables with correlations to WHO Gr II-III at 
0.2 < p < 0.5 were: symptomatic, Osteoporosis, presence 
of edema, current ocp use, statin use, cystic change, 
extracranial extension, memory loss, hyperostosis, site: 
tentorium, Smoking Never, past radiation exposure, 
paresthesia, cranial neuropathy , and current alcoholism. 
Variables with a correlation to WHO Grade II-III with 
p > 0.5 were: treated diabetes, aspirin use, history of 
alcoholism, nausea, hearing loss, diabetes known, 
gait ataxia, calcification, age > = 60, past-hormone 
replacement, brain herniation, and headaches.
Recursive partitioning analysis
Table 2 lists the results of the recursive partitioning 
analysis which was performed using only the variables in 
Table 1.
The initial (most significant) partition identified the 
highest risk group as patients with a prior CVA where 73% 
(8/11) had WHO Grade II-III meningiomas. No significant 
further partitions were identified in that small highest-risk 
group. Among the meningioma patients with no prior 
CVA, the next (most significant) partition occurred with 
a vascular index (VI) of 4, where 54% (7/13) were WHO 
Grade II-III tumors and no significant further partitions 
were identified in the that group. Among the patients with 
no prior CVA and VI = 1–3, the next partition defined 
the group at lowest risk for WHO Grade II-III tumors as 
postmenopausal women (with no stroke and VI = 1–3) 
who had a 10% risk (3/30) of harboring WHO Grade II-III 
meningiomas compared to 35% (7/20) of meningioma 
patients with VI = 1–3 and no prior CVA who weren’t 
postmenopausal females. The recursive partitioning 
analysis thus separated the patients into four risk groups 
with 73, 54, 35 and 10% risks of harboring WHO Gr II-III 
meningiomas. If the two highest risk groups are combined 
as shown in Table 2, then the three risk levels would be 
63, 35 and 10%.
DISCUSSION
To the best of our knowledge, our investigation is 
the first study to demonstrate that clinical factors (past 
history of a cerebrovascular accident and post-menopausal 
state) can be used in order to distinguish atypical/
anaplastic meningiomas from the more common benign 
WHO Grade I meningiomas. A past report only assessed 
brain imaging characteristics and the correlation with 
higher grade tumors and demonstrated that intratumoral 
cystic change and extracranial tumor extension through 
the skull base foramina were more prevalent in atypical/
malignant meningiomas [11]. However, unlike that report, 
our investigation had all pathologic specimens blindly 
reviewed by a Neuropathologist using the current 2007 
WHO classification system. Additionally, we had almost 
twice as many higher-grade tumors which allowed us to 
perform a multivariate analysis.
Although our 36% rate of higher grade meningiomas 
may seem high, it should be noted that our percentage of 
higher grade tumors is similar to that of another recent 
series which noted that re-classification of meningiomas 
by the new WHO 2007 criteria was associated 
with a higher percentage of high grade tumors [6]. 
Additionally, we feel that the relatively high proportion 
of Grade II/III tumors may reflect a referral bias to our 
institution. Because past therapeutic radiation [12], BMI in 
females [13] and hormone replacement therapy [14] have 
been associated with the development of meningioma, 
we felt that assessing the association of these factors 
with the meningioma grade may be important. It should 
be noted that obesity is associated with higher adipose 
aromatase activity, estrogen, androgens, and insulin-like 
growth factor [15]. Despite the majority of our patients 
being female (68%) and obese (median BMI was 31.3), 
females were not more likely than males to be overweight 
Table 1: Factors of univariate significance p < 0.05 (by chi-square or Fisher exact test) distinguishing 
WHO grade 1 versus WHO grade 2–3 meningiomas
Variables % Gr 2–3 with variable Vs. without variable P-value
Prior stroke 73% vs 26% 0.005
CABG 4/4 vs 29% 0.010
Paresis 57% vs 23% 0.008
Vascularity 4 (vs 1–3) 65% vs 28% 0.009
Site: Convexity 49% vs 23% 0.014
Metabolic Syndrome 0/8 vs 40% 0.025
Site: Skull Base 13% vs 42% 0.041
Post-menopausal Female 23% vs 47% 0.045
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(BMI >25, 78% vs 81%) or obese (BMI >30, 55% vs 
50%). Somewhat surprising to us, we found a lower 
incidence of Grade II-III meningiomas in patients with 
metabolic syndrome (0/8 vs 40%, p = 0.024) with similar 
trends for just a diagnosis of obesity (23% vs 44%, 
p = 0.061). We were expecting to find higher rates of 
Grade II-III meningiomas in our premenopausal women 
than postmenopausal women (50% vs 26%), but were 
surprised to find the same 50% rate for the men in our 
series. If estrogen stimulates tumor growth, it is possible 
that it causes faster growing meningiomas to be diagnosed 
earlier and therefore before the onset of menopause. 
If the lower overall incidence of meningiomas in men 
than women included a greater decrease in the incidence 
of WHO Grade I than Grade II-III tumors, then the 
proportion of Grade II-III meningiomas would be higher 
in men than women. Because of the known carcinogenic 
properties of smoking, and the suspected anti-carcinogenic 
properties of statins [16] and cox-2 inhibitors [17], 
we decided to investigate these medications as well as 
hormonal therapy. For completion, we also investigated 
patient co-morbidities and presenting symptoms. We were 
surprised to find the highest rate of Grade II-III tumors 
in the small cohort of patients with prior strokes: 73% 
(8/11) Grade II-III vs 26% without (p = 0.005). We also 
found an association with CABG surgery (p = 0.003 on 
univariate analysis) and a trend for any coronary artery 
disease (p = 0.10). It is possible that factors that give 
rise to CVAs and coronary artery disease also lead to 
intratumoral hypoxia that in turn increases the chances 
of tumor mutation to higher grades. We hypothesize 
that hypoxia may act through the induction of hypoxia 
inducible factor-1 alpha thereby causing the up-regulation 
of pro-angiogenic genes [18]. Therefore, hypoxia in 
the surrounding brain tissue may provide a stimulating 
environment for higher grade characteristics to occur in 
meningioma. Of note, recently, high expression levels of 
VEGF were found in peri-necrotic tumors in Grade III 
meningiomas [19] and HIF-1 has been found in a greater 
percentage of higher grade meningiomas than Grade 
I tumors [20].
Our extensive analysis of imaging characteristics 
identified a significantly higher rates of Grade II-III 
meningiomas with a vascular index of 4/4 (54% vs 20%, 
p = 0.032). By univariate analysis, only tumor sites in the 
convexity (49% vs 23%) and non-skull base sites (42% 
vs 13%) were associated with higher grade tumors. Past 
studies have suggested that non-skull base locations 
[21, 22] were associated higher grade tumors. MRI is the 
mainstay of meningioma imaging because of its superior 
soft tissue resolution and multiplanar capabilities. To date, 
there has been no specific or reliable diagnostic feature 
with conventional or high-end MR imaging techniques 
for the differentiation of Grade II/III meningiomas from 
the more common low grade I tumors [23, 24]. Newer 
imaging techniques such as Diffusion-weighted (DWI), 
MR perfusion (MRP), Diffusion Tensor Imaging (DTI), 
and MR spectroscopy (MRS) have been investigated in 
Table 2: Recursive partitioning analysis (VI = vascularity index, Gr2–3 = WHO Grade 2–3)
Variables % Gr 2–3 with variable Vs. without 
variable
P(Chi-square or Fisher)
Prior CVA: yes versus no 73% (8/11) vs 26% (18/68) p = 0.005
A. Prior CVA 73% (8/11) Subsets: 0.055 *< p <0.52
B. No prior CVA 26%(18/68)
C. Vascularity = 4 vs 1–3 54% (7/13) vs 20% (11/54) 0.032
D. i. Vascularity 4 54% (7/13) Subsets: 0.10 *< p <0.61
 ii. Vascularity ≤3 20% (11/54)
E. Post Menopausal:Y/N 10% (3/30) vs 35% (7/20) p = 0.03
 i. VI ≤3 Post Menopausal 10% (3/30)
 ii. VI ≤3 Other 35% (7/20)
Four Group Model
1. Prior CVA 73% (8/11)
2. No CVA, VI = 4 54% (7/13)
3. No CVA, VI ≤3, not PostMenopausal 35% (7/20)
4. No CVA, VI ≤3, and PostMenopausal 10% (3/30)
*Subset analysis: closest variable for CVA subset was Site: skull base 0/2 vs other 8/9 p = 0.055, closest subsets for no prior 
CVA and VI-4 were brain invasion by imaging and presence of other meningiomas, both p = 0.103.
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smaller series with lesser success and conflicting results. 
[25–31]. Our study shows that the conventional MR 
imaging may be used to differentiate between benign and 
atypical/malignant meningiomas via grade 4/4 vascularity, 
but high grade vascularity is of lesser importance than 
previous history of CVA. As compared to the high end 
modalities like DTI, DWI, DWI and MRS, conventional 
structural imaging is routinely performed, less expensive, 
readily available, and easily applicable for evaluation of 
meningioma. Additionally, our technique for identifying 
Grade II-III meningiomas can allow centers to make 
decisions on patients without having to obtain expensive 
imaging studies that are unavailable from referring centers 
and possibly prevent biopsy in the growing proportion of 
elderly patients [32] who may undergo a brain MRI for 
other reasons.
The main weaknesses of this study are the difficulty 
of assessing so many clinical and imaging variables 
with a limited data set as well as the lack of genetic 
analysis of these tumors. Because of the large numbers 
of variables that were assessed in this limited database, 
this investigation was essentially an exploratory analysis 
that needs to be followed up via the use of a much larger 
database. Including data on genetic mutations in future 
studies would hopefully allow us to correlate specific 
mutations with these different clinical and imaging factors, 
but would even further compound the need for a larger 
database. Our hypothesis that different combinations of 
mutations would be associated with different combinations 
of clinical and imaging factors is why we chose recursive 
partitioning analysis as the next step to assess these 
variables after initial univariate analysis. The four risk 
categories we identified: 1. prior CVA, 2. vascular 
index(vi) = 4(no past CVA history), 3. premenopausal or 
male, vi < 4, no stroke, and 4. Postmenopausal, vi < 4, 
no past CVA history with 73, 54, 35 and 10% rates of 
harboring Grade II-III tumors seems a reasonable start 
towards characterizing these tumors based on clinical and 
imaging variables, but confirmation is needed in larger 
studies. Although long-term follow
CONCLUSION
Meningioma patients with prior CVAs and with a 
grade 4/4 vascularity index are the most likely to have 
WHO Grade II-III tumors (73 & 54% respectively) while 
post-menopausal women without these features are the 
most likely to have WHO Grade I tumors (90%). Further 
study of the associations of clinical and imaging factors 
with grade and clinical behavior are needed to better 
predict behavior of these tumors without biopsy.
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